ImmunityBio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (T cell) immune system. We are developing molecular and product platforms including N-803, Aldoxorubicin, and a second-generation adenovirus vector, based upon our three key modalities of activating natural killer (‘NK’) and T cells, tumoricidal macrophages, and memory T cells.
